What You Should Know:
– Castle Biosciences, a company dedicated to improving health through innovative diagnostic tests that guide patient care announced it has signed a definitive agreement to acquire Capsulomics, Inc., which does business as Previse.
– Previse is a specialized gastrointestinal (GI) health company focusing on diseases related to chronic acid reflux, including esophageal cancer. While the specific terms of the agreement were not disclosed, the transaction is expected to close in the coming weeks, pending customary closing conditions.
Introducing Previse and its Esopredict® Test
Established in 2018, Previse focuses on GI health with a mission to save lives and improve patient health through prevention and the early detection of chronic acid reflux-related diseases, particularly esophageal cancer. The company leverages groundbreaking biomarker technology developed in Dr. Stephen Meltzer’s GI Early Detection Biomarker Lab at the Johns Hopkins University School of Medicine, which is exclusively licensed to Previse. This technology is supported by decades of research and funding from the National Institutes of Health (NIH).
At the forefront of Previse’s offerings is Esopredict®, a highly sensitive epigenetic test. Esopredict® is specifically designed to predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in patients already diagnosed with precancerous Barrett’s esophagus.
